Does the media refer more to LYEL or CRVS?

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 1 mentions for Lyell Immunopharma. Corvus Pharmaceuticals' average media sentiment score of 0.36 beat Lyell Immunopharma's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SVRA or LYEL?

In the previous week, Savara and Savara both had 1 articles in the media. Savara's average media sentiment score of 1.02 beat Lyell Immunopharma's score of 0.00 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MLTX or LYEL?

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 1 mentions for Lyell Immunopharma. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat Lyell Immunopharma's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to JANX or LYEL?

In the previous week, Janux Therapeutics had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Janux Therapeutics and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.00 beat Janux Therapeutics' score of -0.44 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CVAC or LYEL?

Lyell Immunopharma has a consensus price target of $40.86, indicating a potential upside of 288.01%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Lyell Immunopharma (LYEL) Competitors

$10.53 -0.62 (-5.56%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$10.54 +0.01 (+0.09%)

As of 09/23/2026 04:10 PM Eastern

Compare

LYEL vs. CRVS, SVRA, MLTX, JANX, and CVAC

Should you buy Lyell Immunopharma stock or one of its competitors? Lyell Immunopharma's main competitors and comparable companies include Corvus Pharmaceuticals (CRVS), Savara (SVRA), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), and CureVac (CVAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Lyell Immunopharma (NASDAQ:LYEL) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Corvus Pharmaceuticals has lower revenue, but higher earnings than Lyell Immunopharma. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	6,449.63	-$274.45M	-$12.83	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Corvus Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Corvus Pharmaceuticals' return on equity of -36.15% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Lyell Immunopharma presently has a consensus target price of $40.86, suggesting a potential upside of 288.01%. Corvus Pharmaceuticals has a consensus target price of $33.33, suggesting a potential upside of 165.82%. Given Lyell Immunopharma's higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Lyell Immunopharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 1 mentions for Lyell Immunopharma. Corvus Pharmaceuticals' average media sentiment score of 0.36 beat Lyell Immunopharma's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Corvus Pharmaceuticals beats Lyell Immunopharma on 10 of the 14 factors compared between the two stocks.

How does Lyell Immunopharma compare to Savara?

Savara (NASDAQ:SVRA) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Savara has higher earnings, but lower revenue than Lyell Immunopharma. Savara is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Lyell Immunopharma	$40K	6,449.63	-$274.45M	-$12.83	N/A

In the previous week, Savara and Savara both had 1 articles in the media. Savara's average media sentiment score of 1.02 beat Lyell Immunopharma's score of 0.00 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Savara has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Savara currently has a consensus price target of $10.00, suggesting a potential upside of 100.00%. Lyell Immunopharma has a consensus price target of $40.86, suggesting a potential upside of 288.01%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Savara has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Savara's return on equity of -90.28% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

87.9% of Savara shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Savara beats Lyell Immunopharma on 9 of the 13 factors compared between the two stocks.

How does Lyell Immunopharma compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. MoonLake Immunotherapeutics' return on equity of -82.53% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

MoonLake Immunotherapeutics has higher earnings, but lower revenue than Lyell Immunopharma. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Lyell Immunopharma	$40K	6,449.63	-$274.45M	-$12.83	N/A

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Lyell Immunopharma. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 1 mentions for Lyell Immunopharma. MoonLake Immunotherapeutics' average media sentiment score of 0.67 beat Lyell Immunopharma's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MoonLake Immunotherapeutics currently has a consensus target price of $24.57, suggesting a potential upside of 90.48%. Lyell Immunopharma has a consensus target price of $40.86, suggesting a potential upside of 288.01%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

MoonLake Immunotherapeutics beats Lyell Immunopharma on 11 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Janux Therapeutics currently has a consensus target price of $36.46, indicating a potential upside of 120.71%. Lyell Immunopharma has a consensus target price of $40.86, indicating a potential upside of 288.01%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Janux Therapeutics had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for Janux Therapeutics and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.00 beat Janux Therapeutics' score of -0.44 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lyell Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Janux Therapeutics has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -920,285.25%. Janux Therapeutics' return on equity of -11.89% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Janux Therapeutics has a beta of 2.53, indicating that its stock price is 153% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Janux Therapeutics has higher revenue and earnings than Lyell Immunopharma. Janux Therapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	101.00	-$113.62M	-$1.64	N/A
Lyell Immunopharma	$40K	6,449.63	-$274.45M	-$12.83	N/A

Summary

Janux Therapeutics beats Lyell Immunopharma on 11 of the 16 factors compared between the two stocks.

How does Lyell Immunopharma compare to CureVac?

CureVac (NASDAQ:CVAC) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Lyell Immunopharma has a consensus price target of $40.86, indicating a potential upside of 288.01%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

CureVac has a net margin of 199.92% compared to Lyell Immunopharma's net margin of -920,285.25%. CureVac's return on equity of -23.03% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

CureVac has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Lyell Immunopharma	$40K	6,449.63	-$274.45M	-$12.83	N/A

In the previous week, Lyell Immunopharma had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Lyell Immunopharma and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 equaled Lyell Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
Lyell Immunopharma	Neutral

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

17.3% of CureVac shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

CureVac and Lyell Immunopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYEL vs. The Competition

Export

Metric	Lyell Immunopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$273.22M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.82	13.88	274.02	25.69
Price / Sales	6,449.63	1,311.42	632.76	76.07
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.90	15.30	10.44	6.32
Net Income	-$274.45M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-2.50%	-1.71%	-0.66%	0.17%
1 Month Performance	-28.56%	-6.17%	-3.16%	-3.27%
1 Year Performance	-21.71%	30.64%	15.15%	5.58%

Lyell Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYEL Lyell Immunopharma	2.8986 of 5 stars	$10.53 -5.6%	$40.86 +288.0%	-20.1%	$273.22M	$40K	N/A	161
CRVS Corvus Pharmaceuticals	2.1621 of 5 stars	$12.95 -1.2%	$33.33 +157.4%	+104.9%	$1.10B	N/A	N/A	37
SVRA Savara	2.0724 of 5 stars	$5.26 -1.5%	$10.00 +90.1%	+43.7%	$1.10B	N/A	N/A	70	Positive News
MLTX MoonLake Immunotherapeutics	2.3441 of 5 stars	$12.20 -3.8%	$24.57 +101.4%	-75.4%	$1.08B	N/A	N/A	130
JANX Janux Therapeutics	2.605 of 5 stars	$16.44 -5.0%	$36.46 +121.8%	-28.1%	$1.06B	$10M	N/A	113

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYEL) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Competitors

LYEL vs. CRVS, SVRA, MLTX, JANX, and CVAC

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Summary

How does Lyell Immunopharma compare to Savara?

Summary

How does Lyell Immunopharma compare to MoonLake Immunotherapeutics?

Summary

How does Lyell Immunopharma compare to Janux Therapeutics?

Summary

How does Lyell Immunopharma compare to CureVac?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyell Immunopharma (LYEL) Competitors

LYEL vs. CRVS, SVRA, MLTX, JANX, and CVAC

How does Lyell Immunopharma compare to Corvus Pharmaceuticals?

Which has preferable valuation & earnings, LYEL or CRVS?

Is LYEL or CRVS more profitable?

Do analysts prefer LYEL or CRVS?

Which has more risk & volatility, LYEL or CRVS?

Does the media refer more to LYEL or CRVS?

Do institutionals & insiders hold more shares of LYEL or CRVS?

Summary

How does Lyell Immunopharma compare to Savara?

Which has higher earnings & valuation, SVRA or LYEL?

Does the media refer more to SVRA or LYEL?

Which has more risk & volatility, SVRA or LYEL?

Do analysts rate SVRA or LYEL?

Is SVRA or LYEL more profitable?

Do insiders & institutionals hold more shares of SVRA or LYEL?

Summary

How does Lyell Immunopharma compare to MoonLake Immunotherapeutics?

Which has more risk and volatility, MLTX or LYEL?

Is MLTX or LYEL more profitable?

Which has preferable valuation & earnings, MLTX or LYEL?

Do insiders and institutionals hold more shares of MLTX or LYEL?

Does the media prefer MLTX or LYEL?

Do analysts rate MLTX or LYEL?

Summary

How does Lyell Immunopharma compare to Janux Therapeutics?

Do analysts prefer JANX or LYEL?

Do insiders & institutionals believe in JANX or LYEL?

Does the media refer more to JANX or LYEL?

Is JANX or LYEL more profitable?

Which has more risk and volatility, JANX or LYEL?

Which has stronger valuation and earnings, JANX or LYEL?

Summary

How does Lyell Immunopharma compare to CureVac?

Do analysts prefer CVAC or LYEL?

Is CVAC or LYEL more profitable?

Which has better earnings & valuation, CVAC or LYEL?

Does the media refer more to CVAC or LYEL?

Which has more volatility and risk, CVAC or LYEL?

Do insiders and institutionals believe in CVAC or LYEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL vs. The Competition

Lyell Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools